A novel and simple method to prepare γ-hydroxy-α,β-(E)-alkenoic esters from γ-keto-alkynoic esters
摘要:
A method to convert gamma-keto-alkynoic esters to gamma-hydroxy-alpha,beta-(E)-alkenoic esters is described. This functional group transformation was accomplished in one step by means of NaBH, reduction in methanol. (C) 2002 Elsevier Science Ltd. All rights reserved.
Light-induced Ligation of <i>o</i>-Quinodimethanes with Gated Fluorescence Self-reporting
作者:Florian Feist、Leona L. Rodrigues、Sarah L. Walden、Tim W. Krappitz、Tim R. Dargaville、Tanja Weil、Anja S. Goldmann、James P. Blinco、Christopher Barner-Kowollik
DOI:10.1021/jacs.0c02002
日期:2020.4.29
efficient photoligation system, affording a pro-fluorescent Diels-Alder product which on demand converts into an intensively fluorescent naphthalene via E1-elimination in the presence of catalytic amounts of acid. The Diels-Alder reaction of the photocaged diene (o-quinodimethane ether or thioether, o-QDMs) with electron deficient alkynes is induced by UV or visible light. In contrast to previously reported
A Self-Catalyzed Visible Light Driven Thiol Ligation
作者:Leona L. Rodrigues、Aaron S. Micallef、Michael C. Pfrunder、Vinh X. Truong、John C. McMurtrie、Tim R. Dargaville、Anja S. Goldmann、Florian Feist、Christopher Barner-Kowollik
DOI:10.1021/jacs.1c03213
日期:2021.5.19
We introduce a highly efficient ligation system based on a visible light-induced rearrangement affording a thiophenol which rapidly undergoes thiol-Michael additions. Unlike conventional light-triggered thiol–ene/yne systems, which rely on the use of photocaged bases/nucleophiles, (organo)-photo catalysts, or radical photoinitiators, our system provides a light-induced reaction in the absence of any
MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS
申请人:LLINAS-BRUNET Montse
公开号:US20100028300A1
公开(公告)日:2010-02-04
Compounds of formula I:
wherein D, R
4
, R
3
, L
0
, L
1
, L
2
, R
2
and R
C
are defined herein; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.
Compounds of formula (I):
wherein B, X, R
3
, L
0
, L
1
, L
2
, R
2
, R
1
and R
C
are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.
The present invention relates generally to novel calcimimetic compounds and pharmaceutical compositions comprising them. The invention also relates to methods of treating of diseases or disorders related to the function of the calcium sensing receptor using the compounds represented in Formula I.